HUP9800832A3 - Transdermal formulation - Google Patents

Transdermal formulation

Info

Publication number: HUP9800832A3
Authority: HU; Hungary
Prior art keywords: transdermal formulation; transdermal; formulation
Prior art date: 1995-01-30

Application number

HU9800832A

Other languages

English (en)

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-01-30

Filing date

1996-01-16

Publication date

2000-07-28

1996-01-16 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1999-01-28 Publication of HUP9800832A2 publication Critical patent/HUP9800832A2/hu

2000-07-28 Publication of HUP9800832A3 publication Critical patent/HUP9800832A3/hu

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

HU9800832A 1995-01-30 1996-01-16 Transdermal formulation HUP9800832A3 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US38047895A	1995-01-30	1995-01-30

Publications (2)

Publication Number	Publication Date
HUP9800832A2 HUP9800832A2 (hu)	1999-01-28
HUP9800832A3 true HUP9800832A3 (en)	2000-07-28

Family

ID=23501315

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU9800832A HUP9800832A3 (en)	1995-01-30	1996-01-16	Transdermal formulation

Country Status (23)

Country	Link
US (1)	US5980933A (hu)
EP (1)	EP0723781A3 (hu)
JP (1)	JPH10513181A (hu)
KR (1)	KR19980701730A (hu)
AR (1)	AR001790A1 (hu)
AU (1)	AU709379B2 (hu)
BR (1)	BR9600216A (hu)
CA (1)	CA2210711A1 (hu)
CO (1)	CO4700420A1 (hu)
CZ (1)	CZ240297A3 (hu)
EA (1)	EA001083B1 (hu)
HU (1)	HUP9800832A3 (hu)
IL (1)	IL116895A (hu)
NO (1)	NO973471L (hu)
NZ (1)	NZ301197A (hu)
PE (1)	PE17397A1 (hu)
PL (1)	PL321686A1 (hu)
RO (1)	RO117146B1 (hu)
TR (1)	TR199700711T1 (hu)
TW (1)	TW304167B (hu)
WO (1)	WO1996023463A1 (hu)
YU (1)	YU5196A (hu)
ZA (1)	ZA96530B (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6043258A (en) *	1996-08-01	2000-03-28	Eli Lilly And Company	Method for treating disruptive behavior disorders with xanomeline
US6090829A (en) *	1996-08-01	2000-07-18	Eli Lilly And Company	Method for treating excessive aggression
US6117890A (en) *	1996-08-01	2000-09-12	Eli Lilly And Company	Method for treating bipolar disorder
EP0821954A1 (en) *	1996-08-01	1998-02-04	Eli Lilly And Company	Method for treating mental retardation
EP0821956A1 (en) *	1996-08-01	1998-02-04	Eli Lilly And Company	Method for treating disruptive behavior disorders
US6034108A (en) *	1997-07-28	2000-03-07	Eli Lilly And Company	Method for treating mental retardation
US6193993B1 (en) *	1998-03-03	2001-02-27	Eisai Co., Ltd.	Suppository containing an antidementia medicament
US6528529B1 (en)	1998-03-31	2003-03-04	Acadia Pharmaceuticals Inc.	Compounds with activity on muscarinic receptors
JP5106715B2 (ja) *	1999-09-24	2012-12-26	アルロン・ジャパン株式会社	Ｌ−アスコルビン酸、ｌ−アスコルビン酸誘導体の皮膚真皮層への放出方法に使用するための組成物
US7691404B2 (en) *	2000-11-06	2010-04-06	Samyang Corporation	Transdermal delivery system of diclofenac with improved water absorbability and adhesion properties
EP2275095A3 (en)	2005-08-26	2011-08-17	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis with acetylcholinesterase inhibitor
DE102005050431A1 (de) *	2005-10-21	2007-04-26	Lts Lohmann Therapie-Systeme Ag	Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe
US20070259859A1 (en) *	2006-05-04	2007-11-08	De Bruin Natasja M W J	Muscarinic agonists to treat impulse control disorders
DE102010024105A1 (de) *	2010-06-17	2011-12-22	Grünenthal GmbH	Transdermale Verabreichung von Memantin
US8846740B2 (en)	2011-01-04	2014-09-30	Biological Responsibility, Llc	Biotherapeutics for the treatment of infectious diseases
CA2978244A1 (en)	2015-03-06	2016-09-15	Thomas N. Chase	Oxybutynin-xanomeline transdermal therapeutic system combinations
WO2017044693A1 (en)	2015-09-11	2017-03-16	Chase Pharmaceuticals Corporation	Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4316893A (en) *	1975-06-19	1982-02-23	Nelson Research & Development Co.	Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4908027A (en) *	1986-09-12	1990-03-13	Alza Corporation	Subsaturated transdermal therapeutic system having improved release characteristics
US5344656A (en) *	1986-09-12	1994-09-06	Alza Corporation	Subsaturated transdermal therapeutic system having improved release characteristics
MY102980A (en) *	1986-10-31	1993-03-31	Pfizer	Transdermal flux enhancing compositions
ATE76584T1 (de) *	1987-08-28	1992-06-15	Lilly Co Eli	Die permeation verbessernde zusammensetzung.
IT1233860B (it) *	1988-02-08	1992-04-21	Isf Spa	Derivati del peridroazacicloalca (1,2-a) imidazolo ad attivita' nootropa
DE3843239C1 (hu) *	1988-12-22	1990-02-22	Lohmann Therapie Syst Lts
US5043345A (en) *	1989-02-22	1991-08-27	Novo Nordisk A/S	Piperidine compounds and their preparation and use
IE82916B1 (en) *	1990-11-02	2003-06-11	Elan Corp Plc	Formulations and their use in the treatment of neurological diseases
DK198590D0 (da) *	1990-08-21	1990-08-21	Novo Nordisk As	Heterocykliske forbindelser, deres fremstilling og anvendelse
US5238933A (en) *	1991-10-28	1993-08-24	Sri International	Skin permeation enhancer compositions

1995
- 1995-02-17 TW TW084101515A patent/TW304167B/zh active
1996
- 1996-01-16 NZ NZ301197A patent/NZ301197A/en unknown
- 1996-01-16 AU AU46565/96A patent/AU709379B2/en not_active Ceased
- 1996-01-16 JP JP8523556A patent/JPH10513181A/ja active Pending
- 1996-01-16 TR TR97/00711T patent/TR199700711T1/xx unknown
- 1996-01-16 KR KR1019970705126A patent/KR19980701730A/ko not_active Application Discontinuation
- 1996-01-16 CZ CZ972402A patent/CZ240297A3/cs unknown
- 1996-01-16 RO RO97-01416A patent/RO117146B1/ro unknown
- 1996-01-16 HU HU9800832A patent/HUP9800832A3/hu unknown
- 1996-01-16 CA CA002210711A patent/CA2210711A1/en not_active Abandoned
- 1996-01-16 PL PL96321686A patent/PL321686A1/xx unknown
- 1996-01-16 WO PCT/US1996/000504 patent/WO1996023463A1/en not_active Application Discontinuation
- 1996-01-16 EA EA199700151A patent/EA001083B1/ru not_active IP Right Cessation
- 1996-01-22 ZA ZA96530A patent/ZA96530B/xx unknown
- 1996-01-25 EP EP96300535A patent/EP0723781A3/en not_active Withdrawn
- 1996-01-25 BR BR9600216A patent/BR9600216A/pt active Search and Examination
- 1996-01-25 CO CO96003054A patent/CO4700420A1/es unknown
- 1996-01-25 IL IL11689596A patent/IL116895A/xx active IP Right Grant
- 1996-01-26 AR AR33519696A patent/AR001790A1/es not_active Application Discontinuation
- 1996-01-29 YU YU5196A patent/YU5196A/sh unknown
- 1996-02-02 PE PE1996000080A patent/PE17397A1/es not_active Application Discontinuation
1997
- 1997-07-28 NO NO973471A patent/NO973471L/no not_active Application Discontinuation
- 1997-09-29 US US08/942,141 patent/US5980933A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU709379B2 (en)	1999-08-26
HUP9800832A2 (hu)	1999-01-28
IL116895A (en)	2000-08-31
NO973471D0 (no)	1997-07-28
IL116895A0 (en)	1996-05-14
TW304167B (hu)	1997-05-01
YU5196A (sh)	1998-08-14
ZA96530B (en)	1997-07-23
KR19980701730A (ko)	1998-06-25
PE17397A1 (es)	1997-05-21
NO973471L (no)	1997-09-19
EP0723781A2 (en)	1996-07-31
TR199700711T1 (xx)	1998-01-21
JPH10513181A (ja)	1998-12-15
CA2210711A1 (en)	1996-08-08
PL321686A1 (en)	1997-12-22
EP0723781A3 (en)	1996-08-07
RO117146B1 (ro)	2001-11-30
EA001083B1 (ru)	2000-10-30
BR9600216A (pt)	1998-01-06
MX9705723A (es)	1997-11-29
US5980933A (en)	1999-11-09
EA199700151A1 (ru)	1997-12-30
AU4656596A (en)	1996-08-21
AR001790A1 (es)	1997-12-10
CO4700420A1 (es)	1998-12-29
NZ301197A (en)	1999-09-29
CZ240297A3 (cs)	1998-04-15
WO1996023463A1 (en)	1996-08-08

Publication	Publication Date	Title
GB9514842D0 (en)	1995-09-20	Novel formulation
EP0846088A4 (en)	1998-12-23	CEMENT FORMULATION
GB9519363D0 (en)	1995-11-22	Pharmaceutical formulation
GB9402029D0 (en)	1994-03-30	Novel formulation
EP0862431A4 (en)	1999-07-07	PHARMACEUTICAL PREPARATION
ZA96530B (en)	1997-07-23	Transdermal formulation
HUP9802070A3 (en)	2000-09-28	Transdermal formulation
IL116999A0 (en)	1996-06-18	Transdermal formulation
GB9523566D0 (en)	1996-01-17	Pharmaceutical formulation
GB2307857B (en)	1999-01-27	An effervescent formulation
GB9615628D0 (en)	1996-09-04	Formulation
AU6708996A (en)	1997-02-26	Transdermal nitrate formulation
HU9602732D0 (en)	1996-11-28	Lanperisone formulation
ZA96797B (en)	1997-08-01	Transdermal formulation.
GB9404989D0 (en)	1994-04-27	Lipomimetric formulation
GB9508684D0 (en)	1995-06-14	Novel formulation
AUPN493095A0 (en)	1995-09-14	Transdermal composition
GB9423416D0 (en)	1995-01-11	Formulation
GB9412641D0 (en)	1994-08-10	Formulation
GB9412642D0 (en)	1994-08-10	Formulation
ZA952272B (en)	1995-12-12	Formulation
GB9416500D0 (en)	1994-10-12	Formulation
GB9525386D0 (en)	1996-02-14	Pharmaceutical formulation
GB9502786D0 (en)	1995-04-05	Pharmaceutical formulation
GB9509559D0 (en)	1995-07-05	Gel formulation